MX2021004214A - Composiciones y metodos de inmunoterapia. - Google Patents
Composiciones y metodos de inmunoterapia.Info
- Publication number
- MX2021004214A MX2021004214A MX2021004214A MX2021004214A MX2021004214A MX 2021004214 A MX2021004214 A MX 2021004214A MX 2021004214 A MX2021004214 A MX 2021004214A MX 2021004214 A MX2021004214 A MX 2021004214A MX 2021004214 A MX2021004214 A MX 2021004214A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- immunotherapy
- trbc2
- trbc1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan composiciones y métodos para editar, por ejemplo, modificar una secuencia de ADN, dentro de los genes TRBC1, TRBC2 y/o TRAC. Por ejemplo, se proporcionan composiciones y métodos de inmunoterapia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862746522P | 2018-10-16 | 2018-10-16 | |
US201862747037P | 2018-10-17 | 2018-10-17 | |
PCT/US2019/056399 WO2020081613A1 (en) | 2018-10-16 | 2019-10-15 | Compositions and methods for immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004214A true MX2021004214A (es) | 2021-07-15 |
Family
ID=68502008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004214A MX2021004214A (es) | 2018-10-16 | 2019-10-15 | Composiciones y metodos de inmunoterapia. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210340530A1 (es) |
EP (1) | EP3867379A1 (es) |
JP (1) | JP2022512703A (es) |
KR (1) | KR20210091160A (es) |
CN (1) | CN113227374A (es) |
AU (1) | AU2019362879A1 (es) |
BR (1) | BR112021007025A2 (es) |
CA (1) | CA3116132A1 (es) |
CO (1) | CO2021006301A2 (es) |
IL (1) | IL282225A (es) |
MX (1) | MX2021004214A (es) |
PH (1) | PH12021550849A1 (es) |
SG (1) | SG11202103571XA (es) |
TW (1) | TW202035693A (es) |
WO (1) | WO2020081613A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023548588A (ja) * | 2020-10-30 | 2023-11-17 | アーバー バイオテクノロジーズ, インコーポレイテッド | Tracを標的とするrnaガイドを含む組成物及びその使用 |
CR20230303A (es) | 2020-12-11 | 2023-09-01 | Intellia Therapeutics Inc | Composiciones y métodos para reducir el mhc de clase ii en una célula |
IL303971A (en) | 2020-12-23 | 2023-08-01 | Intellia Therapeutics Inc | Preparations and methods for reducing HLA-A in a cell |
IL303970A (en) | 2020-12-23 | 2023-08-01 | Intellia Therapeutics Inc | Compounds and methods for genetic modification of CIITA in a cell |
AU2021411521A1 (en) | 2020-12-30 | 2023-08-03 | Intellia Therapeutics, Inc. | Engineered t cells |
JP2024506016A (ja) | 2021-02-08 | 2024-02-08 | インテリア セラピューティクス,インコーポレイテッド | 免疫療法のためのt細胞免疫グロブリン及びムチンドメイン3(tim3)組成物及び方法 |
EP4288088A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
JP2024505672A (ja) | 2021-02-08 | 2024-02-07 | インテリア セラピューティクス,インコーポレイテッド | 免疫療法のためのナチュラルキラー細胞受容体2b4組成物及び方法 |
WO2022206941A1 (zh) * | 2021-04-02 | 2022-10-06 | 克莱格医学有限公司 | Cs1工程化细胞及其组合物 |
EP4392060A1 (en) | 2021-08-24 | 2024-07-03 | Intellia Therapeutics, Inc. | Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy |
CN118369110A (zh) | 2021-11-03 | 2024-07-19 | 英特利亚治疗股份有限公司 | 用于免疫疗法的cd38组合物和方法 |
WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
WO2023205148A1 (en) | 2022-04-19 | 2023-10-26 | Intellia Therapeutics, Inc. | Chimeric antigen receptor compositions and uses |
WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023245108A2 (en) | 2022-06-16 | 2023-12-21 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
WO2024088401A1 (en) * | 2022-10-28 | 2024-05-02 | CorrectSequence Therapeutics Co., Ltd | Gene editing systems and methods for reducing immunogenicity and graft versus host response |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
WO1995032305A1 (en) | 1994-05-19 | 1995-11-30 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
PL2931898T3 (pl) | 2012-12-12 | 2016-09-30 | Le Cong | Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
AU2013363194B2 (en) | 2012-12-17 | 2019-05-16 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
BR112015021791B1 (pt) | 2013-03-08 | 2022-08-30 | Novartis Ag | Compostos de lipídio catiônico e composições de lipídios e farmacêuticas |
CA2906970C (en) * | 2013-03-21 | 2021-05-18 | Ospedale San Raffaele Srl | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
CA2913830C (en) * | 2013-05-29 | 2021-06-29 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
EP3872066A1 (en) | 2013-12-19 | 2021-09-01 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
KR20230152175A (ko) * | 2014-04-18 | 2023-11-02 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
US20150376587A1 (en) | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
EP3177314B1 (en) | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
CN107249606A (zh) * | 2014-10-31 | 2017-10-13 | 宾夕法尼亚大学董事会 | 改变修饰的t细胞中的基因表达及其用途 |
KR102598856B1 (ko) | 2015-03-03 | 2023-11-07 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
EP3274454B1 (en) * | 2015-03-25 | 2021-08-25 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
KR20180020125A (ko) * | 2015-03-27 | 2018-02-27 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
EP3277294B1 (en) * | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
UA126373C2 (uk) * | 2015-12-04 | 2022-09-28 | Новартіс Аг | Композиція і спосіб для імуноонкології |
US11026969B2 (en) * | 2015-12-23 | 2021-06-08 | Fred Hutchinson Cancer Research Center | High affinity T cell receptors and uses thereof |
WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
AU2017226172B9 (en) * | 2016-03-04 | 2023-08-24 | Editas Medicine, Inc. | CRISPR/Cpf1-related methods, compositions and components for cancer immunotherapy |
TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
JP2019536464A (ja) | 2016-12-08 | 2019-12-19 | インテリア セラピューティクス,インコーポレイテッド | 修飾されたガイドrna |
EP3568467A4 (en) * | 2017-01-10 | 2020-11-25 | The General Hospital Corporation | MODIFIED T LYMPHOCYTES AND THEIR METHODS OF USE |
WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
CA3081320A1 (en) * | 2017-10-30 | 2019-05-09 | Pact Pharma, Inc. | Primary cell gene editing |
CN109750035B (zh) * | 2017-11-02 | 2020-06-05 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
CN107746831B (zh) * | 2017-11-07 | 2019-04-23 | 南京北恒生物科技有限公司 | 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法 |
-
2019
- 2019-10-15 JP JP2021520915A patent/JP2022512703A/ja active Pending
- 2019-10-15 CA CA3116132A patent/CA3116132A1/en active Pending
- 2019-10-15 BR BR112021007025-7A patent/BR112021007025A2/pt unknown
- 2019-10-15 SG SG11202103571XA patent/SG11202103571XA/en unknown
- 2019-10-15 KR KR1020217014333A patent/KR20210091160A/ko unknown
- 2019-10-15 WO PCT/US2019/056399 patent/WO2020081613A1/en active Application Filing
- 2019-10-15 AU AU2019362879A patent/AU2019362879A1/en active Pending
- 2019-10-15 EP EP19801126.4A patent/EP3867379A1/en active Pending
- 2019-10-15 MX MX2021004214A patent/MX2021004214A/es unknown
- 2019-10-15 CN CN201980082863.9A patent/CN113227374A/zh active Pending
- 2019-10-16 TW TW108137354A patent/TW202035693A/zh unknown
-
2021
- 2021-04-11 IL IL282225A patent/IL282225A/en unknown
- 2021-04-15 PH PH12021550849A patent/PH12021550849A1/en unknown
- 2021-04-15 US US17/231,556 patent/US20210340530A1/en active Pending
- 2021-05-13 CO CONC2021/0006301A patent/CO2021006301A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL282225A (en) | 2021-05-31 |
CN113227374A (zh) | 2021-08-06 |
JP2022512703A (ja) | 2022-02-07 |
CA3116132A1 (en) | 2020-04-23 |
US20210340530A1 (en) | 2021-11-04 |
PH12021550849A1 (en) | 2021-12-06 |
WO2020081613A1 (en) | 2020-04-23 |
EP3867379A1 (en) | 2021-08-25 |
SG11202103571XA (en) | 2021-05-28 |
CO2021006301A2 (es) | 2021-06-10 |
AU2019362879A1 (en) | 2021-05-27 |
BR112021007025A2 (pt) | 2021-08-03 |
KR20210091160A (ko) | 2021-07-21 |
TW202035693A (zh) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550849A1 (en) | Compositions and methods for immunotherapy | |
EP3728575A4 (en) | CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF DNA BASES | |
MY194032A (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
WO2018109170A3 (en) | Il-11ra antibodies | |
WO2018109174A3 (en) | Il-11 antibodies | |
EP3585424A4 (en) | MULTISPECIFIC BINDING PROTEINS TARGETED BY CAIX, ANO1, MESOTHELIN, TROP2, CEA OR CLAUDIN-18.2 | |
WO2019089884A3 (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
EP3728588A4 (en) | CAS12A SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | |
EP3728576A4 (en) | CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES | |
EP3692145A4 (en) | NUCLEIC ACID TARGETED EDITING SYSTEMS, METHODS AND COMPOSITIONS | |
EP3684397A4 (en) | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED EDITION OF NUCLEIC ACIDS | |
EP3701025A4 (en) | SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | |
EP4389889A3 (en) | Compositions and methods for editing rna | |
EP3728577A4 (en) | PLANT GENE EDITING SYSTEMS, PROCEDURES AND COMPOSITIONS | |
EP3701042A4 (en) | SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
PH12020550364A1 (en) | Compositions and methods for ttr gene editing and treating attr amyloidosis | |
MY186296A (en) | Novel promoter and use thereof | |
MX2020004043A (es) | Composiciones y métodos para la edición génica de hemofilia a. | |
MX2019004156A (es) | Variantes de endonucleasa homing de receptor de linfocitos t alfa (tcralpha). | |
BR112019018124A2 (pt) | composições e métodos para imunooncologia | |
MX2021003654A (es) | Metodo para seleccionar neoepitopes. | |
MX2021000459A (es) | Metodo para producir celulas t gamma y delta. | |
WO2016138091A3 (en) | Selection methods for genetically-modified t cells | |
WO2019226939A8 (en) | Immune checkpoint inhibitor co-expression vectors |